UBS Keeps Neutral Rating on Treace Medical Concepts (TMCI)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 08 2025
0mins
Should l Buy TMCI?
Source: NASDAQ.COM
UBS Coverage and Price Forecast: UBS has maintained a Neutral recommendation for Treace Medical Concepts (TMCI) as of November 7, 2025, with an average one-year price target of $8.67/share, indicating a potential upside of 94.39% from its current price of $4.46/share.
Projected Revenue and EPS: Treace Medical Concepts is projected to achieve annual revenue of $266 million, reflecting a 21.55% increase, while the expected non-GAAP EPS is -0.59.
Fund Sentiment and Ownership Changes: There are 257 funds reporting positions in TMCI, with a slight decrease in ownership by 3.02% over the last quarter. The average portfolio weight for these funds is 0.08%, which has increased by 1.55%.
Shareholder Activity: Notable changes in shareholder allocations include Armistice Capital increasing its stake by 0.78%, while CIBC Private Wealth Group and Jpmorgan Chase significantly reduced their holdings by 35.91% and 89.97%, respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMCI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMCI
Wall Street analysts forecast TMCI stock price to rise
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 1.570
Low
3.00
Averages
4.87
High
7.50
Current: 1.570
Low
3.00
Averages
4.87
High
7.50
About TMCI
Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Treace Medical Concepts Q4 2025 Earnings Call Insights
- Revenue Performance: Q4 2025 revenue was $62.5 million, a 9% year-over-year decline primarily due to a shift towards lower-priced products, indicating increased competitive pressure in the market.
- Cash Flow Management: As of December 31, 2025, the company had $48.4 million in cash and cash equivalents, with a new credit facility providing an additional $115 million in liquidity, ensuring operational stability for the coming years.
- Future Outlook: The company projects full-year 2026 revenue between $200 million and $212 million, facing a potential 6% decline; however, management remains optimistic about Q4 growth driven by new product launches and increased case volumes.
- Profitability Improvement: Adjusted EBITDA loss for 2025 decreased to $3.9 million from $11 million in 2024, indicating positive progress in cost control and operational efficiency.
See More
Treace Medical Reports Q4 Results and 2026 Guidance
- Earnings Report: Treace Medical Concepts reported a Q4 GAAP EPS of -$0.15, aligning with expectations, while revenue of $62.5 million, down 9% year-over-year, exceeded forecasts by $0.63 million, indicating ongoing market challenges for the company.
- 2026 Revenue Guidance: The company is projecting 2026 revenue between $200 million and $212 million, representing a decline of 6% to 0% compared to 2025, reflecting pressures from weak market demand and intensified competition.
- Adjusted EBITDA Outlook: Treace anticipates an adjusted EBITDA loss of $4 million to $6 million for 2026, compared to a loss of $3.9 million in 2025, highlighting ongoing challenges in restoring profitability.
- Debt Financing Plan: The company announced a debt facility of up to $175 million, aimed at enhancing liquidity and supporting future operational and growth strategies.
See More
Treace Medical Reports 2025 Financial Highlights
- Revenue Growth: Treace Medical reported fourth-quarter revenue of $62.5 million and full-year revenue of $212.7 million, marking a 2% increase year-over-year; however, fourth-quarter revenue decreased by 9% compared to 2024, primarily due to a shift towards lower-priced product sales impacting overall revenue performance.
- Net Loss Situation: The company recorded a net loss of $9.4 million in the fourth quarter and $59.0 million for the full year 2025, an increase from 2024, although adjusted EBITDA loss was reduced by 64%, indicating efforts in cost control and operational efficiency.
- Cash Usage Reduction: Cash usage decreased by 46% to $27.3 million in 2025, reflecting improved financial management, with expectations of a further 50% reduction in cash usage for 2026, providing better funding for future growth initiatives.
- Market Expansion: By the end of 2025, the number of active surgeons increased by 202 to a total of 3,337, representing 33% of U.S. surgeons performing bunion surgeries, indicating significant progress in market penetration and customer base expansion.
See More
UFP Technologies Reports Quarterly Earnings Beat
- Earnings Beat: UFP Technologies reported quarterly earnings of $2.44 per share, surpassing the Zacks consensus estimate of $2.26, indicating stable profitability despite a slight decline from $2.46 a year ago.
- Revenue Miss: The company posted revenues of $148.92 million for the quarter, falling short of the Zacks consensus estimate of $150.5 million, although this reflects a 3.9% year-over-year increase, suggesting ongoing market demand amid challenges.
- Strong Stock Performance: UFP shares have risen approximately 8.9% since the beginning of the year, contrasting with a 0.1% decline in the S&P 500, highlighting the company's relative strength in the market and attracting investor interest.
- Cautious Outlook: With current EPS estimates at $2.55 and revenue expectations at $156.63 million, management's commentary will significantly influence short-term stock movements, prompting investors to closely monitor future earnings estimate revisions.
See More
Treace Medical Concepts to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Treace Medical Concepts plans to release its financial results for Q4 and full year 2025 before trading on February 27, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call at 8:00 am ET to discuss the financial results, requiring investor registration for dial-in numbers and unique PINs, highlighting the company's focus on investor engagement.
- Market Potential: Treace targets the treatment of bunions and related midfoot deformities, with approximately 67 million Americans affected and 1.1 million annual surgical candidates, indicating significant market demand and growth potential.
- Technological Innovation: The launch of Treace's Lapiplasty®3D Bunion Correction System and other related technologies aims to address the root causes of bunions, helping patients return to active lifestyles and enhancing the company's competitive edge in the medical technology sector.
See More
Treace Medical Concepts Reports Q4 2025 Revenue of $62.1M to $62.5M, Beating Consensus
- Revenue Performance: Treace Medical Concepts reported preliminary Q4 2025 revenue of $62.1M to $62.5M, reflecting a 9% decrease year-over-year, although it surpassed the consensus estimate of $61.76M, indicating ongoing business challenges.
- Annual Revenue Growth: For the full year 2025, preliminary revenue was $212.3M to $212.7M, representing a 2% increase compared to the previous year, aligning with the previously provided guidance of $211M to $213M, showcasing consistent growth amidst market conditions.
- Surgeon Increase: The company added approximately 202 new active surgeons in 2025, ending the year with around 3,337 active surgeons, a 6% increase from the prior year, indicating a 33% penetration rate among the estimated 10,000 U.S. surgeons performing bunion surgeries.
- Market Reaction: Treace Medical's stock rose 3.21% in pre-market trading to $2.89, reflecting investor optimism regarding the revenue beat, although the overall declining revenue trend remains a point of concern.
See More
Treace Medical Concepts Q4 2025 Earnings Call Insights
- Revenue Performance: Q4 2025 revenue was $62.5 million, a 9% year-over-year decline primarily due to a shift towards lower-priced products, indicating increased competitive pressure in the market.
- Cash Flow Management: As of December 31, 2025, the company had $48.4 million in cash and cash equivalents, with a new credit facility providing an additional $115 million in liquidity, ensuring operational stability for the coming years.
- Future Outlook: The company projects full-year 2026 revenue between $200 million and $212 million, facing a potential 6% decline; however, management remains optimistic about Q4 growth driven by new product launches and increased case volumes.
- Profitability Improvement: Adjusted EBITDA loss for 2025 decreased to $3.9 million from $11 million in 2024, indicating positive progress in cost control and operational efficiency.
See More
Treace Medical Reports Q4 Results and 2026 Guidance
- Earnings Report: Treace Medical Concepts reported a Q4 GAAP EPS of -$0.15, aligning with expectations, while revenue of $62.5 million, down 9% year-over-year, exceeded forecasts by $0.63 million, indicating ongoing market challenges for the company.
- 2026 Revenue Guidance: The company is projecting 2026 revenue between $200 million and $212 million, representing a decline of 6% to 0% compared to 2025, reflecting pressures from weak market demand and intensified competition.
- Adjusted EBITDA Outlook: Treace anticipates an adjusted EBITDA loss of $4 million to $6 million for 2026, compared to a loss of $3.9 million in 2025, highlighting ongoing challenges in restoring profitability.
- Debt Financing Plan: The company announced a debt facility of up to $175 million, aimed at enhancing liquidity and supporting future operational and growth strategies.
See More
Treace Medical Reports 2025 Financial Highlights
- Revenue Growth: Treace Medical reported fourth-quarter revenue of $62.5 million and full-year revenue of $212.7 million, marking a 2% increase year-over-year; however, fourth-quarter revenue decreased by 9% compared to 2024, primarily due to a shift towards lower-priced product sales impacting overall revenue performance.
- Net Loss Situation: The company recorded a net loss of $9.4 million in the fourth quarter and $59.0 million for the full year 2025, an increase from 2024, although adjusted EBITDA loss was reduced by 64%, indicating efforts in cost control and operational efficiency.
- Cash Usage Reduction: Cash usage decreased by 46% to $27.3 million in 2025, reflecting improved financial management, with expectations of a further 50% reduction in cash usage for 2026, providing better funding for future growth initiatives.
- Market Expansion: By the end of 2025, the number of active surgeons increased by 202 to a total of 3,337, representing 33% of U.S. surgeons performing bunion surgeries, indicating significant progress in market penetration and customer base expansion.
See More
UFP Technologies Reports Quarterly Earnings Beat
- Earnings Beat: UFP Technologies reported quarterly earnings of $2.44 per share, surpassing the Zacks consensus estimate of $2.26, indicating stable profitability despite a slight decline from $2.46 a year ago.
- Revenue Miss: The company posted revenues of $148.92 million for the quarter, falling short of the Zacks consensus estimate of $150.5 million, although this reflects a 3.9% year-over-year increase, suggesting ongoing market demand amid challenges.
- Strong Stock Performance: UFP shares have risen approximately 8.9% since the beginning of the year, contrasting with a 0.1% decline in the S&P 500, highlighting the company's relative strength in the market and attracting investor interest.
- Cautious Outlook: With current EPS estimates at $2.55 and revenue expectations at $156.63 million, management's commentary will significantly influence short-term stock movements, prompting investors to closely monitor future earnings estimate revisions.
See More
Treace Medical Concepts to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Treace Medical Concepts plans to release its financial results for Q4 and full year 2025 before trading on February 27, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call at 8:00 am ET to discuss the financial results, requiring investor registration for dial-in numbers and unique PINs, highlighting the company's focus on investor engagement.
- Market Potential: Treace targets the treatment of bunions and related midfoot deformities, with approximately 67 million Americans affected and 1.1 million annual surgical candidates, indicating significant market demand and growth potential.
- Technological Innovation: The launch of Treace's Lapiplasty®3D Bunion Correction System and other related technologies aims to address the root causes of bunions, helping patients return to active lifestyles and enhancing the company's competitive edge in the medical technology sector.
See More
Treace Medical Concepts Reports Q4 2025 Revenue of $62.1M to $62.5M, Beating Consensus
- Revenue Performance: Treace Medical Concepts reported preliminary Q4 2025 revenue of $62.1M to $62.5M, reflecting a 9% decrease year-over-year, although it surpassed the consensus estimate of $61.76M, indicating ongoing business challenges.
- Annual Revenue Growth: For the full year 2025, preliminary revenue was $212.3M to $212.7M, representing a 2% increase compared to the previous year, aligning with the previously provided guidance of $211M to $213M, showcasing consistent growth amidst market conditions.
- Surgeon Increase: The company added approximately 202 new active surgeons in 2025, ending the year with around 3,337 active surgeons, a 6% increase from the prior year, indicating a 33% penetration rate among the estimated 10,000 U.S. surgeons performing bunion surgeries.
- Market Reaction: Treace Medical's stock rose 3.21% in pre-market trading to $2.89, reflecting investor optimism regarding the revenue beat, although the overall declining revenue trend remains a point of concern.
See More
